Table 2.
Medication use during current major depressive episode and lifetime (N=22)
| Medication/Treatment* | Current | Lifetime | ||
|---|---|---|---|---|
| N | % | N | % | |
| Antidepressants | ||||
| • SSRI | 14 | 64 | 21 | 95 |
| • Venlafaxine | 9 | 41 | 16 | 73 |
| • Duloxetine | 8 | 36 | 15 | 68 |
| • Bupropion | 8 | 36 | 14 | 64 |
| • MAOI | 4 | 18 | 8 | 36 |
| • Mirtazapine | 3 | 14 | 7 | 32 |
| • TCA | 3 | 14 | 6 | 27 |
| • Nefazodone | 3 | 14 | 3 | 14 |
| • Trazodone | 1 | 5 | 2 | 9 |
| Atypical Antipsychotics | 4 | 18 | 9 | 41 |
| • Quetiapine | 3 | 14 | 5 | 23 |
| • Aripiprazole | 1 | 5 | 4 | 18 |
| • Risperidone | 1 | 5 | 4 | 18 |
| • Ziprasidone | 1 | 5 | 3 | 14 |
| • Olanzapine | 0 | 0 | 2 | 9 |
| Anticonvulsants | ||||
| • Lamotrigine | 2 | 9 | 6 | 27 |
| • Valproate | 2 | 9 | 6 | 27 |
| • Oxcarbazepine | 2 | 9 | 2 | 9 |
| • Gabapentin | 0 | 0 | 3 | 14 |
| • Topiramate | 0 | 0 | 1 | 5 |
| Other | ||||
| • Benzodiazepines | 7 | 32 | 9 | 41 |
| • Stimulants | 5 | 23 | 5 | 23 |
| • Modafinil | 2 | 9 | 2 | 9 |
| • Desvenlafaxine | 4 | 18 | 4 | 18 |
| • ECT | 3 | 14 | 10 | 45 |
| • Lithium | 2 | 9 | 7 | 32 |
| • Hypnotics | 2 | 9 | 4 | 18 |
| • Thyroid Augmentation | 2 | 9 | 3 | 14 |
| • Amoxapine | 1 | 5 | 1 | 5 |
| • Pregabalin | 1 | 5 | 1 | 5 |
| • Atomoxetine | 0 | 0 | 1 | 5 |
| • Donepezil | 0 | 0 | 1 | 5 |
| • Methylphenidate | 0 | 0 | 1 | 5 |
| • Pramipexole | 0 | 0 | 1 | 5 |
Abbreviations: ECT, electroconvulsive therapy; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; VNS, vagal nerve stimulation.
*
Adequate trial based on the Antidepressant Treatment History Form-modified (ATHF-modified), modified to include adequate trial definition for newer antidepressants and pramipexole.